Drug Trial Radar · NCT05753813
Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
22
Planned (sponsor's estimate)
Start
Dec 15, 2023
Primary completion
Jan 30, 2027
Study completion Jan 30, 2027
Sponsor
- Lead sponsor
- Queen's Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Hawaii Foundation
- First posted
- Mar 3, 2023
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 54 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections.
Conditions
- Bacterial Vaginosis
- Vulvovaginal Candidiasis
Interventions
PhexxiDrug
intravaginal gel twice weekly for 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess participant's baseline vaginal microbiome makeupTime frame: Within one week of recruitment, unless menstruating. If this is the case, the participant will be asked to wait 10 days from the cessation of menses in order to allow restoration of baseline vaginal microbiome
- To assess if the use of Phexxi causes changes in the vaginal microbiome from baseline after thirty days of useTime frame: 30 days after baseline vaginal swab collection
- To assess if the use of Phexxi causes changes in the vaginal microbiomeTime frame: 60 days after baseline vaginal swab collection
- To assess participant's baseline vulvovaginitis symptomsTime frame: On day of recruitment to the study
- To assess if the use of Phexxi decreases vulvovaginitis symptoms in study participantsTime frame: 30 days after baseline vaginal swab collection
- To assess if the use of Phexxi decreases vulvovaginitis symptoms in study participantsTime frame: 60 days after baseline vaginal swab collection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Queens Medical Center, 1004 Clinic POB1
Honolulu, Hawaii · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.